Core Insights - Hypertrophic Cardiomyopathy (HCM) is the most common single-gene hereditary heart disease, characterized by asymmetric hypertrophy of the myocardium, with obstructive HCM having a lower survival rate [2][23] - Mavacamten, a first-in-class myosin inhibitor, targets the core pathophysiological mechanisms of HCM, representing a significant advancement in treatment options [2][17] Group 1: Disease Overview - HCM affects approximately 0.2% to 0.5% of the global population, with an estimated 2 million patients in China [2][23] - Patients with obstructive HCM experience symptoms such as dyspnea, fatigue, chest pain, and syncope, which severely limit their daily activities and mental well-being [2][23] Group 2: Mavacamten Development - Mavacamten is the first drug to provide targeted intervention at the pathophysiological level, differing from traditional symptomatic treatments like beta-blockers and calcium channel blockers [4][25] - The EXPLORER-HCM trial demonstrated that Mavacamten significantly improves exercise capacity, left ventricular outflow tract (LVOT) obstruction, and overall health status compared to placebo [6][27] Group 3: Clinical Trials in China - The EXPLORER-CN trial, led by Professor Zhang Shuyang, is the first randomized, double-blind, placebo-controlled study specifically for symptomatic obstructive HCM patients in China [12][28] - Results from EXPLORER-CN showed significant improvements in LVOT peak pressure gradient and other clinical parameters after 30 weeks of treatment with Mavacamten [13][32] Group 4: Safety and Efficacy - Mavacamten treatment resulted in consistent benefits across various subgroups, including gender, age, and baseline NYHA classification, with no new safety signals identified [13][28] - The drug demonstrated positive effects on cardiac structure and diastolic function, as evidenced by reductions in left ventricular mass index and wall thickness [14][34] Group 5: Global Contribution and Future Prospects - Chinese clinical data and research have enriched the global evidence base for Mavacamten, highlighting the role of Chinese researchers in advancing scientific understanding of HCM [16][37] - Mavacamten was approved for use in China in April 2024, marking a significant milestone in providing a root-cause treatment option for obstructive HCM patients [18][17]

Core Viewpoint - Sudden Cardiac Death (SCD) is a major global health issue, particularly in patients with Hypertrophic Cardiomyopathy (HCM), where current clinical guidelines show low performance and inconsistent accuracy in risk assessment [1][2]. Group 1 - SCD has an annual incidence of 50-100 cases per 100,000 people in North America and Europe, with ventricular arrhythmias being the primary mechanism [1]. - Implantable Cardioverter Defibrillators (ICDs) can effectively terminate arrhythmias and reduce mortality in high-risk patients when implanted preventively [1]. - The current risk stratification paradigm, based on Left Ventricular Ejection Fraction (LVEF) below 30%-35%, is primarily applicable to ischemic and dilated cardiomyopathy patients but fails to provide comprehensive risk assessment [2]. Group 2 - A recent study published by researchers from Johns Hopkins University introduced a multimodal AI model named MAARS (Multimodal Artificial intelligence for Ventricular Arrhythmia Risk Stratification) to predict arrhythmic death in HCM patients [3][4]. - MAARS utilizes a Transformer-based neural network that learns from electronic health records, echocardiograms, radiology reports, and contrast-enhanced cardiac MRI, which is a unique aspect of the model [8]. Group 3 - MAARS demonstrated an Area Under the Curve (AUC) of 0.89 in internal cohorts and 0.81 in external cohorts, significantly outperforming current clinical guidelines which have AUCs ranging from 0.27-0.35 (internal) and 0.22-0.30 (external) [10]. - Unlike clinical guidelines, MAARS shows fairness across different population subgroups, enhancing the transparency of AI predictions and identifying risk factors for further investigation [10]. - Overall, MAARS is a powerful and reliable clinical decision support tool for risk stratification of SCD in HCM patients, with potential to significantly improve clinical decision-making and patient care through integration with automated data extraction systems or as a concept validation for personalized patient care [10].